RxDoctor Payments Data

Carrie Wolfberg, MD

Cardiovascular Disease · Torrington, CTNPI 1952481186

Payments from drug & device makers

$2,384in general payments, 2019–2025

Across 111 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$459
  • Abbott$326
  • Amgen$252
  • E.r. Squibb & Sons, L.L.C.$223
  • AstraZeneca$218
  • Pfizer$192
  • plus $714 from 16 others

What the payments were for

  • Food & beverage$2,35599%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,384 in reported general payments places this provider in the 55th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$98,630
Medicare patients
1,000
Services billed
2,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$186,895
JardianceEmpagliflozin67$62,836
Repatha SureclickEvolocumab69$54,858
XareltoRivaroxaban46$45,353
EntrestoSacubitril/Valsartan19$28,953
Repatha PushtronexEvolocumab19$19,543
VascepaIcosapent Ethyl12$4,285
Metoprolol Succinate225$2,781
Ezetimibe106$2,447
Rosuvastatin Calcium129$2,220
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$2,013
Valsartan53$1,158
Amiodarone Hcl22$1,060
Amlodipine Besylate136$808
Atorvastatin Calcium80$635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$186,895196 claims
Boehringer IngelheimJardiance$459$62,83667 claims
Johnson & JohnsonXarelto$137$45,35346 claims
NovartisEntresto$156$28,95319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →